Subscribe to RSS feed

WIKINDX Resources

Abate, D., Taye, B., Abseno, M., & Biadgilign, S. (2012). Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in addis ababa, ethiopia. BMC Research Notes, 5, 
Resource type: Journal Article
DOI: 10.1186/1756-0500-5-462
ID no. (ISBN etc.): 17560500
BibTeX citation key: Abate2012
View all bibliographic details
Categories: General
Keywords: Drug resistance, Drug susceptibility, epidemiology, MDR-TB, Trend
Creators: Abate, Abseno, Biadgilign, Taye
Collection: BMC Research Notes
Background: Drug-resistant TB has emerged as a major challenge facing TB prevention and control efforts. In Ethiopia, the extent/trend of drug resistance TB is not well known. The aim of this study was to determine the pattern and trend of resistance to first line anti-TB drugs among culture positive retreatment cases at St.Peters TB Specialized Hospital. Findings. A hospital based retrospective study was used to assess the pattern of anti-TB drug resistance among previously treated TB patients referred to St.Peters TB Specialized Hospital from January 2004-December 2008 Gregorian calendar(GC) for better diagnosis and treatment. Among 376 culture positive for M. tuberculosis one hundred and two (27.1%) were susceptible to all of the four first line anti-TB drugs -Isoniazid (INH), Rifampicin (RIF), Ethambutol (ETB) & Streptomycin (STM). While 274 (72.9%) were resistant to at least one drug. Any resistance to STM (67.3%) was found to be the most common and the prevalence of MDR-TB was 174 (46.3%). Trend in resistance rate among re-treatment cases from 2004 to 2008 showed a significant increase for any drug as well as for INH, RIF, and MDR resistance (P <0.05 for trend). Conclusions: There has been an increasing trend in drug resistance in recent years, particularly in retreatment cases. Therefore, establishing advanced diagnostic facilities for early detection of MDR-TB and expanding second line treatment center to treat MDR-TB patients and to prevent its transmission is recommended. ©2012 Abate et al.; licensee BioMed Central Ltd.